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Abstract
Hoxa1 belongs to the Hox family of homeodomain transcription factors involved in patterning embryonic territories and
governing organogenetic processes. In addition to its developmental functions, Hoxa1 has been shown to be an oncogene
and to be overexpressed in the mammary gland in response to a deregulation of the autocrine growth hormone. It has
therefore been suggested that Hoxa1 plays a pivotal role in the process linking autocrine growth hormone misregulation
and mammary carcinogenesis. Like most Hox proteins, Hoxa1 can interact with Pbx proteins. This interaction relies on a Hox
hexapeptidic sequence centred on conserved Tryptophan and Methionine residues. To address the importance of the Hox-
Pbx interaction for the oncogenic activity of Hoxa1, we characterized here the properties of a Hoxa1 variant with substituted
residues in the hexapeptide and demonstrate that the Hoxa1 mutant lost its ability to stimulate cell proliferation,
anchorage-independent cell growth, and loss of contact inhibition. Therefore, the hexapeptide motif of Hoxa1 is required to
confer its oncogenic activity, supporting the view that this activity relies on the ability of Hoxa1 to interact with Pbx.
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Introduction
Hox genes define a subset of the homeobox gene family coding
for homeodomain transcription factors involved in mammalian
embryogenesis and organogenesis [1,2,3]. They contribute to
pattern the main body axis and the limbs and they control cell fate
determination in several organs and cell lineages [4,5,6].
Misregulation of Hox genes has been reported to be associated
with the development of a variety of human cancers, including
those of skin [7], breast [8], lung [9], prostate, and blood cells [10].
Whether this association between tumorigenesis and Hox gene
misexpression reveals that Hox genes actually contribute to the
transformation process, is an issue that remains largely unresolved.
Only a few Hox proteins have actually been proved to act on
cancer progression, either as oncoproteins or tumor suppressors
[11,12,13].
In the normal mammary gland, distinct Hox genes exhibit
specific expression patterns and functions along its successive
development phases, from prenatal stages to lactation at adulthood
[14]. Hoxc6 is expressed during mammary development and this
expression declines during pregnancy [15] while Hoxa9, Hoxb9 and
Hoxd9 are required for the expansion and/or differentiation of the
mammary epithelial ductal system in response to pregnancy [16]
and targetted disruption of Hoxd10, leads to a failure in alveolar
expansion in late pregnancy and concomitant lactation defect
[17].
In addition to their involvement in the normal mammary gland
biology, studies have shown that some Hox genes are repressed or
overexpressed in mammary carcinomas and therefore influence
cancer progression. For example, when HOXA10 is expressed in
both benign and malignant breast tissue in adult women, it
impacts on tumor cell phenotype by decreasing cell invasiveness
and upregulating the tumor suppressor gene p53 [18]. HOXA5 is
also a positive regulator of p53 in the normal breast tissue. In
human breast tumors, p53 expression can be dramatically
decreased by a compromised HOXA5 function [19], and
expression of HOXA5 in epithelial cancer cells displaying wild-
type p53 led to apoptotic cell death. HOXD10 also has a tumor
suppressor function. Its expression is progressively reduced in
epithelial cells as malignancy increases in breast tumors and
restored Hoxd10 activity inhibits tumor development in mouse
xenografts and impairs migration of tumor cells [20]. HOXA9
positively regulates BRCA1 expression and represses breast tumor
growth and malignancy [21]. While several Hox proteins act as
tumor suppressors, HOXB7 is overexpressed in primary breast
carcinoma and metastasis, and it stimulates tumor progression by
promoting epithelial-mesenchymal transition [22].
Hoxa1 is one of the first Hox genes to be expressed during
embryonic development [23]. Gene inactivation has demonstrated
its functional importance for hindbrain segmentation, hindbrain
patterning, inner and middle ear organogenesis and skull basis
morphogenesis [24]. While Hoxa1 is not expressed in the adult
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upregulated in mammary carcinomas [8,15,17,25]. Hoxa1 can
be activated in mammary epithelial cells in response to an
increased autocrine growth hormone (hGH) stimulation which
leads to cell transformation as well as cancer progression and
invasiveness [26,27,28]. Forced expression of Hoxa1 is sufficient to
provoke the oncogenic transformation of immortalized human
mammary epithelial cells and formation of tumors in vivo after cell
grafting in mice [29].
Several Hoxa1 target genes have been identified to take part in
carcinogenesis. Genes coding for signal tranducing proteins active
in the p44/42 mitogen-activated protein (MAP) kinase pathway
(GRB2, MEK1, SDFR1) are downstream targets of Hoxa1 [30].
Some p44/42 MAP kinase-regulated genes (IER3, EPAS1,
PCNA, catalase) can also be modulated by Hoxa1 [30]. Hoxa1
has further been demonstrated to stimulate oncogenicity by
activating STAT3, STAT5B [31] and the anti-apoptotic gene BCL-
2, with the consequence to dramatically reduce the apoptotic cell
death [29]. Another gene directly regulated by Hoxa1, EphA2, has
also been reported to transform mammary epithelial cells and to
promote tumor formation in vivo [32]. Expression of EphA2 and its
ligand ephrin-A1 has been observed in the vasculature of human
primary breast cancer and of breast-tumor-cell-line-derived
tumors in nude mice. Thus, EphA2 has been proposed to be
involved in tumor-induced angiogenesis [33]. Furthermore,
Hoxa1 promotes the activation of Cyclin-D1 required for the
autocrine hGH-mediated cell cycling stimulation in mammary
carcinoma [29,34]. Finally, an increased Hoxa1 expression is not
only observed upon autocrine hGH stimulation but can also occur
as a consequence of E-cadherin-mediated signalling. Hoxa1
activation is required for E-cadherin-dependent anchorage-
independent proliferation and decreases apoptotic cell death of
human mammary carcinoma cells [35].
As transcription factors, Hox proteins cooperate with other
transcription regulators or coregulators [36,37,38,39]. Such
interactions affect the DNA binding specificity and/or the
transcriptional activity of the Hox proteins [40,41,42,43,44].
Among the best characterized Hox cofactors are the Three-
Amino-acid-Loop-Extension (TALE) family of homeodomain
proteins [45,46], which can be subdivided into four groups
according to sequence similarities: PBC (Pbx, ceh-20, exd), TGIF,
MEIS (Meis, ceh-25, hth, Prep) and IRO [47,48]. The Pbx proteins
belong to the PBC group of TALE proteins able to cooperatively
bind to DNA with Hox proteins of paralogy groups 1–10. In vitro
studies have shown that Hox/Pbx heterodimers display a greater
affinity and specificity for cognate DNA sequences than the Hox
monomers [41,49]. The interaction between Hox proteins of
paralog groups 1–8 and Pbx relies on a conserved hexapeptide
sequence located N-terminal to the Hox homeodomain and
sharing core Tryptophan and Methionine residues. Hox proteins
of paralog groups 9 and 10 do not contain this hexapeptide, they
only present a conserved Tryptophan allowing their interaction
with Pbx [50,51,52,53].
Mutational analysis of Hoxa1 has revealed that the Tryptophan
and Methionine residues of the conserved hexapeptide are critical
for the cooperative interaction between Hoxa1 and Pbx1 [42].
Moreover, the mutant Hoxa1 protein was found to be inactive on
cognate target enhancers in live cells [54]. Finally, in vivo studies
have demonstrated that knock-in mice for mutations resulting in a
WM-to-AA substitution in the hexapeptide of Hoxa1 display
hindbrain, cranial nerve and skeletal defects corresponding to the
phenotype of the Hoxa1 knock-out [55]. Together, these data
support that the embryonic function of Hoxa1 requires the
integrity of its hexapeptide motif, which in turn suggests that the
activity of the protein critically relies on its partnership with Pbx.
Considering the requirement for an intact hexapeptide for the
normalactivityofHoxa1,wehaveaddressedhereitsimportancefor
the oncogenic potential of the protein. Proliferation, anchorage-
independent growth and foci assays have been performed to
compare the cellular responses to wild-type or hexapeptide mutant
Hoxa1. Our data demonstrate that the WM-to-AA substitution in
the Hoxa1 hexapeptide severely impairs its oncogenic properties,
which therefore suggests the Hoxa1/Pbx partnership to be involved
in its ability to transform mammary epithelial cells. Possible
implications in terms of therapeutic applications are discussed.
Results
The Hoxa1 protein mutated in its hexapeptide has lost
the ability to stimulate mammary cells proliferation
Hoxa1 has previously been shown to affect the phenotype of the
epithelioid mammary tumor cell line MCF7 in a way that is
indicative of its pro-oncogenic activity, as its forced expression
enhanced cell proliferation and anchorage-independent growth
[29,35]. To address the importance of the Hoxa1 hexapeptide for
its mammary carcinogenic activity, we generated stable MCF7 cell
clones for the expression of distinct Hoxa1 variants. The Hoxa1
gene encodes two alternatively spliced mRNA. A 2.2 kb long
mRNA resulting from a single splicing event encodes the full-
length protein. A shorter mRNA is obtained when a second,
alternative splicing event takes place, generating a frameshift and
coding for a truncated protein devoid of homeodomain and
hexapeptide sequences [56]. The truncated Hoxa1 variant has
been shown to interact with Hoxa1 and Pbx1 and to interfere with
the activity of the full-length Hoxa1 [57]. cDNA based expression
vectors derived from the long Hoxa1 mRNA could theoretically
generate two mRNA species as the alternative splicing event can
take place. A first expression vector was designed based on the full
length wild-type cDNA (Hoxa1
WT). A second vector was
generated in which the alternative splice site was mutated leading
to an Isoleucine-to-Valine substitution at position 115 in the
Hoxa1 sequence (Hoxa1
I-V) which does not affect the Hoxa1
activity in transcription assays [58]. Finally, based on this second
construct an expression vector was generated for the Hoxa1
mutant with the core Tryptophan and Methionine residues of the
hexapeptide substituted for Alanines (Hoxa1
WM-AA).
To control the relative activity of the variant Hoxa1 proteins,
transient co-transfection experiments were first carried out
involving a luciferase reporter construct as well as expression
vectors for both Pbx1a and Prep1. The pML-EphA2-r42B-luc
reporter plasmid contains a cognate Hoxa1 target enhancer
derived from the EphA2 gene, a well-known mammary oncogene.
Prep1 is a TALE homeodomain protein which stimulates the
nuclear entry of Pbx and which enhances the ability of Hox-Pbx
complexes to activate transcription [38]. Cotransfection experi-
ments revealed that the EphA2-r42B-luc reporter was significantly
activated in MCF7 cells expressing Hoxa1
WT and Hoxa1
I-V
proteins, but not in Hoxa1
WM-AA expressing cells (Figure 1A). To
exclude that the loss of transcriptional activation ability observed
for Hoxa1
WM-AA was due to a loss in protein stability, the relative
abundance of Hoxa1 proteins in transfected cells was evaluated by
western blots. Although these western blots are not quantitative, it
clearly appeared that the Hoxa1
WM-AA was properly expressed, at
a similar level as the Hoxa1
WT and Hoxa1
I-V variants (Figure 1B).
Two stable MCF7 clones were obtained for each expression vector
in addition to control clones transfected with the empty vector (CTL).
Hoxa1 expression in the selected clones was verified by RT-PCR.
Hoxa1, Pbx and Oncogenesis
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Hoxa1 mRNA was detected in the MCF7 clones for the Hoxa1
WT,
-Hoxa1
I-V and -Hoxa1
WM-AA vectors (630 bp, Figure 2A), while no
Hoxa1 expression was detected in CTL clones or non-transfected
MCF7 cells (not shown). In addition, the fragment expected for the
short length Hoxa1 mRNA was never detected in the MCF7-
Hoxa1
WT cells, suggesting that the alternative splicing does not take
place and that the truncated Hoxa1 is not expressed. Therefore, the
MCF7clonesfortheHoxa1
WT and Hoxa1
I-V constructs both express
only the full length protein and onlydiffer by the fact that the Hoxa1
I-
V clones express a single amino-acid variant of Hoxa1. Finally, we
also verified that the PBX1 gene is endogenously expressed in all cell
clones (Figure 2A), so that in all clones the Hoxa1 protein can
potentially interact with its cofactor. Quantitative RT-PCR con-
firmed that Hoxa1 expression level is not significantly different
between the Hoxa1 clones ensuring that cell phenotype changes
which could be observed are not due to differences in Hoxa1
expression (data not shown).
To check that the constitutively expressed Hoxa1 variants
appropriately reach the cell nucleus to achieve gene regulatory roles,
immuno-cytochemical assays were performed (Figure 2B). As
expected, the CTL clones did not show Hoxa1 expression. As a
positive control, transiently transfected MCF7 cells displayed a strong
signal for Hoxa1 in cell nuclei. Nuclear staining of Hoxa1 was
detected in all stable clones (Figure 2B). Immuno-cytodetection assay
revealed that the endogenously expressed PBX1 protein was the
PBX1B isoformand that it also localized into the nucleus of the MCF7
cells and stablytransfected derivatives (Figure 2Cand data not shown).
To evaluate if the Hoxa1 variants expressed in the stably
transfected clones are transcriptionally active, the pML-EphA2-
r42B-luc reporter construct was transiently co-transfected in the
stable clones in combination with expression vectors for both
Pbx1a and Prep1. Cotransfection experiments revealed that the
EphA2-r42B-luc reporter was significantly activated in the clones
expressing Hoxa1
WT and Hoxa1
I-V proteins, but not in Hoxa1
WM-
AA expressing clones (Figure 3). That the Hoxa1
WM-AA variant was
unable to activate the target reporter was confirmed by transient
transfection which allows a strong overexpression of the protein
[54] (data not shown). These results therefore confirm that MCF7-
Hoxa1
WT and MCF7-Hoxa1
I-V clones express active Hoxa1
proteins, whereas the Hoxa1
WM-AA variant has lost the ability to
transactivate target genes.
We then addressed the effect of the hexapeptide substitution on
cell growth stimulation provided by Hoxa1. Cell proliferation rate
was twice higher for the MCF7-Hoxa1
WT and MCF7-Hoxa1
I-V
clones than for control clones or clones expressing Hoxa1
WM-AA
mutant (Figure 4A). Interestingly, clones transfected for Hoxa1
WM-
AA grew at the same rate as the control cells transfected with the
empty vector. Complementary to proliferation assays, cell growth
was recorded over two weeks of culture, with cell counting after 4,
7, 9, 11, 14 and 16 days of culture. This experiment confirmed
that clones expressing the Hoxa1
WT and Hoxa1
I-V proteins grew
twice faster than cells transfected for the Hoxa1
WM-AA mutant
(Figure 4B). Cells expressing Hoxa1
WM-AA however grew slower
than the controls, suggesting that this mutant Hoxa1 could exert a
dominant negative effect in this cell growth assay (see Discussion).
Together these data confirm that the Hoxa1 protein stimulates
mammary cell proliferation and that this growth stimulation effect
is abrogated by the hexapeptide mutation.
Anchorage independent cell growth is provided by the
wild-type Hoxa1 while not by the hexapeptide mutant
Tumor formation is associated with anchorage independent cell
growth. This propensity of cells to grow with loose substrate
attachment can be assayed in soft-agar medium. Cell suspensions
are mixed in low percentage agar and left for growing over 17
days. Cells able to grow in an anchorage-independent manner will
form colonies easily viewed after crystal violet staining. Cell clones
were grown in soft agar and colonies were counted after 17 days of
culture. As depicted on Figure 5, a low number of colonies were
formed by the CTL cells. In contrast about three times more
colonies grew from the Hoxa1
WT and Hoxa1
I-V expressing clones.
Finally, the Hoxa1
WM-AA clones produced a similar amount of
colonies as the control clones, demonstrating that the mutant
Hoxa1 protein has lost its ability to promote anchorage-
independent cell growth (Figure 5).
Hoxa1
WM-AA expressing cells show contact inhibition
Tumor cells loose the contact inhibition normally observed for
epithelial cells in vivo or in vitro when cells reach confluence. The
loss of contact inhibition induced by oncogenes is classically
monitored by a foci formation assay. In this assay, cells are
Figure 1. Transcriptional activity and relative expression of
Hoxa1 variants. (A) The Hoxa1 target reporter EphA2-r42B-luc is
activated in MCF7 cells in the presence of expression vectors for
Hoxa1
WT, Hoxa1
I-V while not in the presence of Hoxa1
WM-AA or of an
empty (CTL) plasmid. In each experiment, the pML-EphA2-r42B-luc
reporter plasmid was transfected in combination with expression
vectors for both Prep1 and Pbx1a. Results were calculated by a
luciferase/b-galactosidase ratio and represented as means 6 S.D. of
triplicates. ***, p,0.001 (ANOVA2). (B) Detection of Hoxa1 variant
proteins from whole cell lysates obtained from transiently transfected
MCF7 cells reveal that Hoxa1
WT, Hoxa1
I-V and Hoxa1
WM-AA proteins are
equally expressed and stable. No Hoxa1 protein could be detected from
MCF7 cells or from cells transfected with an empty (CTL) expression
vector. Detection of constitutively expressed b-actin protein was
performed as control load.
doi:10.1371/journal.pone.0025247.g001
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for three weeks. Untransfected MCF7 cells displaying an
epithelioı ¨d phenotype are responsive to contact inhibition and
show very few, if any, foci after three weeks of culture. The
transient transfection of Prep1a and Pbx1 expression vectors in
control clones did not enhance foci formation (CTL, Figure 6). In
contrast, transfecting Hoxa1
WT or Hoxa1
I-V together with the
cofactors resulted in the appearance of numerous foci (Figure 5).
Most significantly, when the hexapeptide mutant was cotrans-
fected with the cofactors, a small amount of foci was observed,
which was not distinguishable from the situation where only the
cofactors were expressed. This assay therefore shows that the
Hoxa1
WM-AA protein has lost the ability to relieve the cells from
their contact inhibition. This again supports that the hexapeptide
mutation suppresses the oncogenic potential of Hoxa1.
Discussion
While a continuously increasing number of studies report
correlations between Hox genes misexpression and several types of
cancers, only a few Hox genes have been identified to actually
impact on cancer progression, as genuine oncogenes or tumor
suppressors [11,13]. Hoxa1 has been reported to be abnormally
expressed in breast carcinomas [8,25] and to act as a mammary
oncogene [29]. Like many other Hox proteins, Hoxa1 can interact
with the TALE homeoproteins Pbx. This interaction relies on a
hexapeptidic motif of Hoxa1. It has indeed been demonstrated
that substituting two amino acids (WM to AA) in this hexapeptide
motif abrogated the formation of Hoxa1-Pbx1a complexes on
cognate target DNA sequences [59,60]. Further, we have
previously shown that disrupting the Hoxa1-Pbx interaction
severely impaired its developmental activity. Indeed, by substitut-
ing these two amino acids (WM to AA) critically involved in the
docking to Pbx, we generated knockin mice which phenocopied
the Hoxa1 knockout, suggesting that the Hoxa1-Pbx partnership is
crucial to the Hoxa1 function. [55]
Here, we addressed the importance of the hexapeptide integrity
for the oncogenic potential of Hoxa1. We demonstrate that the
Hoxa1
WM-AA hexapeptide mutant lost its ability to stimulate cell
Figure 2. Characterization of MCF7 clones for the constitutive expression of Hoxa1 variants. (A) Expression of Hoxa1, Neomycin
resistance (Neo), Pbx1 and b-actin genes was detected by RT-PCR. While MCF7 cells do not express Hoxa1, clones obtained the stable transfection of
Hoxa1
WT, Hoxa1
I-V and Hoxa1
WM-AA coding plasmids express the Hoxa1 variants at similar levels (b-actin used as reference). All cells express the
endogenous Pbx1 gene. (B) The Hoxa1 and (C) PBX1B protein immunolocalisation reveals that both proteins localize into the cell nucleus.
doi:10.1371/journal.pone.0025247.g002
Figure 3. Activation of a Hoxa1 target reporter in mammary
carcinoma cell clones. The Hoxa1 target reporter EphA2-r42B-luc is
activated in cell clones for Hoxa1
WT and Hoxa1
I-V while not in Hoxa1
WM-
AA clones. In each experiment, the pML-EphA2-r42B-luc reporter
plasmid was transfected in combination with expression vectors for
both Prep1 and Pbx1a. The constitutively active pCMV-LacZ reporter
plasmid was added as a transfection control. Results were calculated by
a luciferase/b-galactosidase ratio, pooled for each type of clones and
represented as means 6 S.D. of triplicates. *, p,0.05 and ***, p,0.001
(ANOVA 2).
doi:10.1371/journal.pone.0025247.g003
Hoxa1, Pbx and Oncogenesis
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contact inhibition. Thus, this hexapeptide motif is required to
confer to Hoxa1 its oncogenic potential, supporting the view that
this critically relies on the ability of Hoxa1 to interact with Pbx.
The involvement of Hox-Pbx interaction in cancer stimulation
is supported by several studies aiming at evaluating the impact of
HOX-PBX dimer disrupting molecules on cancer cell properties.
These molecules were either synthetic peptides mimicking the
hexapeptide motif from HOX proteins [61,62,63,64], or mimetic
compounds obtained from molecular modelling and combinatorial
libraries [65]. Such antagonist molecules have been shown to
specifically block proliferation and promote apoptosis of melano-
ma, ovarian, pancreatic and non-small-cell lung cancer cells in
which members of the HOX family are deregulated [61,63].
Blocking the activity of HOX protein by interfering with their
binding to PBX co-factor also reduced the growth of tumor cells in
vivo [61,63]. The cell behavior modifications induced by these
inhibitors of the HOX-PBX interaction were further correlated to
transcriptional changes indicative of a loss of malignancy
[61,62,63]. In a similar approach, Fernandez et al. [66] showed
that a dominant negative mutant of PBX reduced the oncogenic
activity of HoxB7 and correlated well with increased apoptosis and
decreased cell cycling. Finally, mutating the hexapeptide of
HOXB4 has also shown to impair its ability to provoke cell
transformation [67]. All these studies together with our data
suggest that the interaction between Hox and Pbx proteins is a
potential therapeutic target for distinct types of cancers.
Nevertheless, disrupting the Hox-Pbx interaction could not
always result in a simple functional invalidation of the Hox
activity. Indeed, a double mutation in the hexapeptide motif of the
mouse Hoxb8 did not result in a loss-of-function of the protein as it
is shown here for Hoxa1 and as we previously showed for the
Hoxa1
WM-AA knockin mice [55,68]. The knockin allele of Hoxb8
coding for a hexapeptide mutant protein indeed appeared as a
neomorph. Thus, in contrast to what stands for Hoxa1, the
hexapeptide-mediated interaction with Pbx would rather have a
modulatory implication on the activity of Hoxb8. The use of
hexapeptide mimetic peptides or of related molecules in a
therapeutical perspective should then be considered on a case-
by-case basis [68] and it would be worth addressing the functional
importance of the hexapeptide for additional Hox proteins
involved in cancer stimulation.
Although the integrity of the hexapeptide is required for the
oncogenic activity of Hoxa1, this does not necessarily imply that the
Hoxa1-Pbx interaction is involved in the Hoxa1-mediated oncogen-
esis. We cannot formally exclude that the loss of oncogenic potential
due to the hexapeptide mutation is independent of the loss of Pbx
interaction. Indeed, the hexapeptide might be involved in other
critical interactions as has been shown for other Hox proteins. For
example, study of the hexapeptide motif of Antennapedia, a Hox
protein from drosophila, has revealed that it is involved in an
interaction with a TATA-binding associated factor linking Antenna-
pedia to the transcripitonal machinery [69]. However, hexapeptide-
mediated interactions with other proteins than Pbx have never been
reported for Hoxa1, its paralogues or its invertebrate homologues.
Intriguingly, while Hoxa1 expression stimulated cell growth,
expression of the Hoxa1
WM-AA variant resulted in a decrease in cell
growth with respect to control cells in one of our assays. This suggests
that beside the loss of transcription activity and Pbx interaction
displayed by Hoxa1
WM-AA, this variant could exert a dominant
negative effect towards proteins involved in cell proliferation. It is
highly expectable that Hoxa1 is involved in diverse protein-protein
interactions other than with the sole TALE transcription factors. The
WM-AA substitution would not invalidate all those interactions so
that although being inactive in mediating Hoxa1-Pbx dimer
formation on DNA, this mutant still interacting with other factors
to be identified could impair the activity of some of those interactors
thereby acting as a dominant negative.
The present study identifies the hexapeptide as a key
determinant of Hoxa1 oncogenic properties. Considering the
growing body of evidence that Hox proteins can be critical actors
in several kinds of cancers, deciphering the modalities of their
oncogenic or oncosuppressive activities will undoubtedly be
relevant for the clinic and future therapeutic developments.
Materials and Methods
Plasmid constructions
Expression vectors for Hoxa1 derivatives were obtained from the
previously described pGIH309, pGIH327 and pGIH328 constructs
[54]. Shortly, pGIH309 bears the wild-type Hoxa1 cDNA
Figure 4. The expression of Hoxa1
WM-AA in human mammary
carcinoma cells does not result in increased cell proliferation
and growth. (A) WST-1 based proliferation assays were performed for
MCF7-Hoxa1
WT,M C F 7 - H o x a 1
I-V,M C F 7 - H o x a 1
WM-AA and MCF7-CTL
clones. The proliferation index was determined for each clone as
described in Materials and Methods. Results were pooled for each type
of clones and represented as means 6 S.D. of triplicates. *, p,0.05
(ANOVA 2). (B) Cells for MCF7-Hoxa1
WT, MCF7-Hoxa1
I-V, MCF7-Hoxa1
WM-
AA and MCF7-CTL clones were inoculated, kept in culture for 16 days
and counted after day 4, 7, 9, 11, 14 and 16. Growth curves represent
the mean of four independent experiments.
doi:10.1371/journal.pone.0025247.g004
Hoxa1, Pbx and Oncogenesis
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WT)underthe controlofaCMV enhancer/promotermodule.
pGIH327 is similar to pGIH309 but harbours a mutant Hoxa1
cDNAinwhichanalternativesplicesitehasbeenmutated(Hoxa1
I-V)
which in turn results in an I-to-V amino acid substitution in the
Hoxa1 protein [58]. pGIH328 also contains a Hoxa1 cDNA
sequence invalidated for the alternate splicing and is additionally
modified to code for the WM-to-AA substitution in the Hoxa1
hexapeptide (Hoxa1
WM-AA). To allow selecting stablytransfected cells
for these expression vectors, a Neomycin resistance marker has been
added in pGIH309, pGIH327 and pGIH328 to give rise to
pGIH364, pGIH367 and pGIH368, respectively. An empty vector
only coding for Neomycin resistance has been obtained as control for
all the experiments (pNeo). Details regarding the plasmid constructs
are available upon request. Reporter plasmids EphA2-r4-Luc [70]
and pCMV-LacZ [71], as well as expression vectors for Pbx1a [54]
and Prep1 [72] have been described elsewhere.
Cell culture and transfections
The MCF7 cell line (ATCC #HTB-22) and transfected
derivatives were maintained at 37uC in a humidified, 5% CO2
atmosphere in DMEM 4.5 g/L D-glucose supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 IU/ml penicillin
and 100 mg/ml streptomycin and 2 mM L-glutamine (Gibco).
MCF7 cells were stably transfected with pNeo, pGI364, pGIH367
and pGIH368 plasmids, by use of the Gene Pulser Xcell System
(Bio Rad). Transfectants were selected in 1 mg/ml G418 (Gibco).
Transient co-transfections for luciferase reporter assays were
carried out with the Transfectin reagent (BioRad). One day prior
to transfection 80 000 cells per well were seeded in 24-well plates.
Each transfection involved a total amount of 1.05 mg of DNA,
containing: 0.625 mg of reporter plasmid (pML-EphA2-r42B-luc);
0.125 mg of Hox expression vector; 0.125 mg of Pbx1a expression
vector; 0.125 mg of Prep1 expression vector; and 0.05 mgo f
internal standard reporter plasmid (pCMV-LacZ). In co-transfec-
tions aimed at detecting foci formation, 200 000 cells were seeded
in 36-mm Petri culture dishes. They have been transfected after
24 hours with 1 mg of Hoxa1 or control expression vector and
1 mg of each of the Pbx1a and Prep1 expression vectors with the
Transfectin reagent (BioRad). As positive control, a plasmid
coding for the oncogene hRAS, was used.
Figure 5. The expression of Hoxa1
WM-AA in human mammary carcinoma cells does not result in increased anchorage independent
cell growth. Cells were grown in soft agar and colonies were revealed by crystal violet staining (A) MCF7-Hoxa1
WT and MCF7-Hoxa1
I-V cells
produced a lot of colonies in soft agar while CTL and MCF7-Hoxa1
WM-AA only provide a modest colony growth. (B) For each culture, colonies were
counted in three random microscopic fields at 16X magnification. Results were pooled for each type of clones and represented as means 6 S.D of
triplicates. **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0025247.g005
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For detection of Hoxa1 proteins expression, transiently
transfected cells were lysed with RIPA buffer (1 mM EDTA,
0.1% SDS, 1% Nonidet P40, 0.5% NaDeoxycholate, 50 mM
TrisHCl pH7.5, 250 mM NaCl, protease inhibitors). Whole cell
lysates were run on a SDS-PAGE, blotted on a nitrocellulose
membrane and revealed with an anti-Hoxa1 rabbit antibody (1/
500; Sigma HPA004933), anti-rabbit bovine IgG-horseradish
peroxidase (HRP)-conjugated antibody (1/3000; SantaCruz sc-
2379). The protein load for western blotting was controlled by
detecting b-actin with a HRP conjugated anti-b-actin antibody (1/
3000 Sigma A3854).
Reverse transcriptase-PCR
Total RNA was extracted using Trizol Reagent (Invitrogen). RNA
quantification was performed on a Nanodrop apparatus (Thermo
Scientific). One mg of RNA was then reverse transcribed into cDNA
and amplified with the Expand Reverse Transcriptase (Roche) and
Taq Polymerase (Westburg) respectively. Primers for RT-PCR were
as follows: Hoxa1 (forward), 59-CCTTATGGCCCCTATGGA-39;
Hoxa1 (reverse), 59-TTCTCAGATGATTCTTCCGTT-39; b-actin
(forward), 59-GCTGGAAGGTGGACAGCGA-39; b-actin (reverse),
59-GGCATCGTGATGGACTCCG-39; Neo
R (forward), 59-AAT-
GAACTGCAGGACGAGGC-39; Neo
R (reverse), 59-C A A C G C -
TATGTCCTGATAGC-39; Pbx1 (forward), 59-TCAGAGATG-
GATGCGAGGGCGAAGAGACGC-39; Pbx1 (reverse), 59-
TTTGGCAGCATAAATATTGGC-39.A l lR N As a m p l e sw e r e
treated with DNase I to avoid genomic DNA contamination.
Immunostaining and fluorescence microscopy
Immunodetections of Hoxa1 and PBX1B were performed
either on stably or on transiently transfected cells. In both cases,
cells were seeded on glass cover-slips in 24-well plates. For stable
clones, twenty-hours after seeding, cells were fixed in 4% formalin
and blocked in 10% powder milk. Cells were incubated at 4uC
with the anti-Hoxa1 rabbit antibody (1/50, Sigma HPA004933) or
anti-Pbx1B (41.1) mouse antibody (1/50, Santacruz sc-101852)
overnight. They were washed and incubated respectively with a
fluorescein coupled anti-rabbit IgG antibody (1/100, GE Health-
care N1034) or with an Alexa Fluor 555 coupled anti-mouse IgG
antibody (1/1000, Cell Signaling 4409) for 1 h. Cover-slips were
mounted in vectashield with DAPI medium (Vector Laboratories
H1200) and viewed under Polyvar microscope (Reichert Jung).
For transiently transfected cells, the same procedure was applied,
except that cells were firstly transfected 24 hours after seeding and
then processed for immunostaining 24 hours after transfection.
Luciferase reporter assay
Cells were harvested 48 h after transfection for enzymatic
assays. Lysis and enzymatic activity dosages were performed with
the b-gal Reporter Gene Assay (Chemiluminescent) kit (Roche)
and the Luciferase Reporter Gene Assay (High Sensitivity) kit
(Roche), according to the instructions provided by the manufac-
turer. For each transfection, the constitutively active pCMV-LacZ
reporter was used as a control, so that the relative luciferase
activity was calculated by a luciferase/b-galactosidase ratio.
Cell proliferation and growth assays
The WST-1 assay is a colorimetric method based on the
cleavage by mitochondrial dehydrogenase of the tetrazolium salt
generating a detectable product, formazan. Two thousand cells for
each MCF7 clone were seeded in 96-well plates in complete
DMEM, with 2 wells devoid of cells as blank samples. Cells were
allowed to seed overnight at 37uC in 5% CO2. Twenty-four hours
after seeding, medium was changed with DMEM supplemented
with 1% FBS. Two days after seeding, 10 ml of WST-1 reagent
was added to the cells medium for 4 hours. The absorbance for
the formazan product (440 nm) and the background control
(620 nm) were recorded every hour by a multiplate reader
Figure 6. Hoxa1
WT and Hoxa1
I-V relieve MCF7 cells from
contact inhibition, while expressing Hoxa1
WM-AA does not.
MCF7 cells were transiently transfected for Hoxa1
WT, Hoxa1
I-V and
Hoxa1
WM-AA, together with Pbx1a and Prep1 cofactors, and grown for
three weeks. Controls included cells transfected for the potent
oncogene hRAS or cells transfected for Pbx1a and Prep1 only. Foci
formation was observed for hRAS, Hoxa1
WT and Hoxa1
I-V transfected
cells (arrowheads) while not for CTL and Hoxa1
WM-AA cells.
doi:10.1371/journal.pone.0025247.g006
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difference between the measures at 440 nm and 620 nm was
calculated and inserted on a graph as a function of time. The slope
of each curve was calculated and represented the cell proliferation
index.
For growth recording, 5.0 10
4 cells of each MCF7 clone were
seeded in 6-well plates in complete DMEM. Medium was changed
every 2 days. After 4, 7, 9, 11, 14 and 16 days of culture, cells were
counted. Values were reported on a graph representing the cell
growth of MCF7 clones.
Anchorage-independent growth assay
Anchorage-independent growth was assayed in soft agar. Cells
were plated into 24-well plates in growth medium (DMEM)
containing 0.3% agarose, on top of a layer of 0.6% agarose gel
(Sigma A9045). After 17 days, cells were stained with crystal violet
for 1 h and colonies were counted under a binocular (Wild M3B –
Van Hopplynus Instrument) in three random microscopic fields at
16X magnification.
Foci formation assay
MCF7 cells were seeded in 36-mm Petri dish and co-transfected
as mentioned above. Once confluence was reached, medium was
changed every 3 days. After 2 weeks, cultures were fixed with
formalin, stained with 1% rhodamine B (Sigma R6626) and
washed with PBS to bleach the non-focal monolayer. Foci were
observed under a binocular (Leitz Wetzlar).
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